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esting Regeneration of Human Myocardium
ithout Knowing the Identity and the
umber of Effective Bone Marrow Cells
ransplanted: Are the Results Meaningful?
e read with great interest and attention the intriguing IACT
tudy by Strauer et al. in a recent issue of the Journal (1). We wish
o highlight a few points that might be crucial for the correct
nterpretation of the results.
The method used to derive the ejection fraction by ventriculog-
aphy is not specified in the study. If it was the biplane Simpson’s
ethod the conclusions might be questionable. This method, also
hen applied to echocardiographic images, requires significant
eometric assumptions and suffers from limited accuracy and
eproducibility (2). Both ventriculography and echocardiography
o not represent the optimal modalities (especially when compared
o cardiac magnetic resonance imaging) for repeated measurements
n small-sized follow-up studies (3). The sample size of the IACT
tudy seems inadequate to confer sufficient statistical power for
ntergroup comparisons.
Regional systolic functional analysis was used to detect changes
n infarct size. However, significant differences in the amount of
iable myocardium and the transmural extent of the necrosis in the
reated versus untreated dysfunctional myocardial segments may
ave potentially influenced the degree as well as the time-course of
unctional recovery in the two study groups (4).
Because the nature of the trial was nonrandomized, this study
as no control/placebo group. Therefore, the placebo effect and/or
dditional balloon expansion during cell administration cannot be
uled out.
The bone marrow cells (BMCs) used in the IACT study were
btained from a noncloned cell preparation, and, therefore, it is
mpossible to ascertain the number and nature of the putative
egenerating cells administered. Because of that, it cannot be
etermined whether the protocol used in this study does in fact test
he regenerative potential of the BMCs (5). Indeed, the amount of
yocardial regeneration in the treated patients, if any, cannot be
easured owing to technical and ethical reasons.
Even if we believe in the myocardial regenerative potential of
MCs, it has to be pointed out that the controversy surrounding
his topic has yet to be properly addressed (5). Strauer et al.
1) have further documented the safety and feasibility of BMC
njection in patients with chronic heart failure; however, their data
o not address some of the most controversial issues facing this
herapy.
In particular, because they could not reasonably deal with the
ssue of myocardial regeneration, Strauer et al. (1) offer an alter-
ative explanation for their results. This paracrine interpretation
rgues that the injected BMCs release angiogenic ligands, enhance
ardiomyocyte survival, and may recruit resident cardiac stem cells (CSCs) (5), but it is equally lacking in real data. Recently, it has
lso been proposed that apoptosis of transplanted cells modulates
ocal tissue reactions, leading to improved cardiac outcome (6).
hether these putative cell-related effects play any significant role
r whether they are specific to BMCs or just the consequence of
ny cell transplantation await the proper experiments.
What does remain clear is that at present there is no documented
echanistic explanation for the reported improvement in cardiac
unction in postinfarct patients treated with autologous BMCs.
Overall, we are persuaded that the relative contributions of the
ransplanted BMCs and/or the recruited CSCs on de novo
yogenesis and vasculogenesis will be unlikely resolved by small
linical trials. The identity of the therapeutic cells present in the
one marrow must be established and their biological properties
efined before planning large clinical trials.
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EPLY
e appreciate the high interest in our recently published data,
ecause it raises some interesting concerns that were considered
efore initiating our investigation.
First, ever since myocardial stem cell therapy in humans was
rst reported in 2001 by our group (1), both the effectiveness and
he safety of this type of therapy in acute myocardial infarction
ave been increasingly established. This is now also relevant for old
i.e., chronic) myocardial infarction. The use of mononuclear bone
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July 18, 2006:411–20arrow cells—in both acute and chronic infarction—represents a
nique chance for the compromised heart muscle because all of the
hree bone marrow cell fractions (CD34 positive, CD34 negative,
D133 angioblasts) contribute to its myocardial regeneration.
hus, the speculative assumption of apoptotic-induced cell mod-
lation, which may be discussed for acutely infarcted myocardium,
s neither conclusive nor necessary in chronic coronary disease. All
ur chronic patients (n  36) (the IACT study) fulfilled the same
nclusion criteria (e.g., randomization; equal procedural cardiac
atheterization techniques; standardized cell isolation and harvest-
ng) (2,3).
Moreover, both the intracoronary cell delivery via balloon
atheter and the production of enhanced environment by balloon-
nduced ischemia during the course of intracoronary cell transplan-
ation were the same. The identity and number of bone marrow
tem cells transplanted were exactly quantified for each patient
2,3), and the exact quantification of regional ventricular function
nd contractility has been extensively validated in our clinic (4).
As to our actual knowledge, the regenerative potential of
ononuclear bone marrow cells refers at least to four different
echanisms: direct cell transdifferentiation, cytokine-mediated
timulation of nondestroyed myocytes, mobilization of intrinsic
tem cells, and cell fusion. The high (four-fold) mitotic potency of
order zone myocardium (5) suggests that several of these four
echanisms together may play a role.
Finally, what remains clear is that intracoronary stem cell
ransplantation, as has been described by our original report (1), is
n exclusive procedure for regenerating acutely and/or chronically
ompromised myocardium. We agree that it is desirable that larger
linical trials, as in acute infarction, may also confirm these
eneficial data for chronic coronary heart disease.
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ost Advantage of Different
ardioverter-Defibrillator Devices
mong patients without a bradycardia indication for pacing, the
resumed benefits of routine dual- versus single-chamber implant-
ble cardioverter-defibrillator (ICD) usage, including a potential
eduction in inappropriate shocks by enhancement of supraven-
ricular tachycardia detection, remain unproven (1). Adding to the
ist of soft reasons for routine dual-chamber device usage is the
ecent study in JACC by Goldberger et al. (2), who analyzed the
nancial costs associated with a strategy of universal dual-chamber
CD placement versus implantation of a single-chamber ICD
ollowed by upgrade as clinically indicated. That analysis suggests
hat even with upgrade rates as low as 5%, a universal dual-
hamber implant approach could be the most cost-effective.
owever, the analysis could not consider two costs, which, though
ot monetary, are of primary importance.
First, the addition of implanting an atrial lead is associated, not
urprisingly, with at least a doubling of device and lead-related
omplication rates (3–5). This price would be paid by our patients
irectly should a universal dual-chamber implant approach be
aken.
Second, there would be an unmeasurable price paid by our
rofession as a whole were we to abandon our ethical obligation to
ur individual patients by employing a strategy that asks them to
houlder the burden of unnecessary medical procedures in the
nterests of reducing “costs to the system.” Surgeons accept
erforming 1 or 2 unnecessary appendectomies in 10 to minimize
he chance of perforated appendicitis (6). Are we to accept
erforming more than 9 unnecessary procedures in 10 and placing
ore than 90% of our patients in (unnecessary) harm’s way to save
ome money? The clinical benefits that we might realistically
xpect our individual patients to experience from a universal dual-
ersus single-chamber implantation approach must first be estab-
ished before any cost analysis such as this one should have any
nfluence on ethical practice.
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